Carbapenem-Resistant Acinetobacter baumannii
Hospitalized Infections
85.6% of cases were hospitalized
30-day Crude Mortality
- Overall cases:
- 12.6%
- Cases with a sterile site specimen:
- 19.5%
- Cases with a urine specimen:
- 3.7%
- Cases with a wound specimen:
- 7.4%
- Cases with a lower respiratory tract specimen:
- 18.5%
Infections by Race
- White:
- 37.8%
- Black or African American:
- 56.2%
- Asian:
- 1.1%
- Other or unknown race:
- 4.9%
MuGSI Data Profile
Carbapenem-Resistant Acinetobacter baumannii
Acinetobacter baumannii is a species of bacteria that frequently contaminates healthcare facility surfaces and shared medical equipment. The organism is commonly resistant to many antibiotics. Resistance to carbapenems further reduces patient treatment options. Most carbapenem-resistant A. baumannii (CRAB) produce carbapenemases, which are enzymes that inactivate carbapenems and other β-lactam antibiotics. CRAB can share the genetic code for carbapenemases with other bacteria, rapidly spreading resistance.
CRAB can cause a variety of infections, including wound, bloodstream, and urinary tract infections. Treatment options for infections caused by CRAB are extremely limited.
CRAB spreads through direct or indirect contact with patients infected or colonized with CRAB or contaminated environmental surfaces and equipment. Patients in healthcare settings who receive complex medical care, including having invasive devices and long courses of antibiotics, or with severe or chronic wounds are at most risk for CRAB.
CDC provides guidelines and tools to the healthcare community to help prevent CRAB as well as provides resources to help the public safeguard their own health.
CRAB Infections in EIP Sites
CRAB Infections in EIP Sites
Rates of CRAB in EIP surveillance area
Note: CRAB surveillance has included urine and normally sterile site specimens. Starting in 2021, surveillance for CRAB expanded to also include wound and lower respiratory tract specimens, which resulted in a higher incidence rate than in previous years.
Footnotes
- Surveillance areas have changed over time. The number of EIP sites participating in surveillance is as follows: 2012 – 3 sites; 2013 – 7 sites; 2014-2017 – 8 sites; 2018 to present – 9 sites.